Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis

• Conditions: Multiple Sclerosis; Cognitive Impairment

• Registration Number: NCT01250665
• Lead Sponsor: Cantonal Hospital of St. Gallen

Brief Summary

This study is a cross sectional study of patients diagnosed with clinically isolated syndrome (CIS) and RRMS, who will undergo a series of tests to assess cognitive impairment, fatigue severity and depressive symptoms. Cognitive impairment will be assessed with Multiple Sclerosis Inventory Cognition (MUSIC) and symbol digit modalities test (SDMT), fatigue severity will be measured with the Fatigue Scale for Motor and Cognitive Functions (FSMC) and depressive symptoms with the Beck Depression Inventory (BDI). All tests mentioned above are validated for MS patients. In the second step we will use our large longitudinal database of serial MRI examinations from which a linear measurement of CCI will be retrospectively calculated.

Detailed Description

Not available

Study Timeline

• Status Verified: 2010-11
• Study First Submitted: 2010-11-30
• Study First Submitted QC: 2010-11-30
• Last Update Submitted: 2010-11-30
• Study First Posted: 2010-12-01
• Last Update Posted: 2010-12-01
• Study Start: 2011-01
• Primary Completion: 2011-06
• Study Completion: 2011-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• Patients between 18 and 55 years at presentation
• Diagnosis of relapsing-remitting MS according to revised McDonald criteria 2005, clinically isolated syndrome suggestive of MS
• Patients treated with interferon-beta 1b
• Untreated patients
• EDSS under 5.5

Exclusion Criteria

• Brain pathology other than MS
• Known history of head trauma
• Pure spinal manifestation of demyelization
• Neuromyelitis optica
• Primary and secondary progressive MS
• Benzodiazepine intake within the last three months
• Relapse within the last three months
• Steroid intake within the last three months
• History of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse
• No informed consent
• Insufficient knowledge of German

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Multiple Sclerosis Inventory Cognition (MUSIC)		MUSIC is a cognitive screening instrument. It assesses the cognitive core deficit in MS (mental flexibility, attention, information processing speed, memory and inhibitory control) and includes 3 items derived from a factorial analysis to examine cognitive, motor and psychosocial fatigue, respectively.
Annual Corpus Callosum Index decrease		Corpus callosum index (CCI) is an easy to use MRI marker for estimating brain atrophy in patients with MS. Demonstrated correlation of CCI and atrophy has been measured with brain parenchymal fraction.

Secondary Outcome Measures

Name	Time	Method
Corpus callosum Index at baseline		The CCI at baseline will be measured from MRI findings acquired at diagnosis of clinically isolated syndrome.
Time to clinically definite MS		This is the time in months then patients diagnosed with CIS go on to develop clinically definite MS (CDMS). CDMS will be diagnosed if patients fulfill the criteria for remitting relapsing MS according to Poser (Poser 1983) or McDonald (McDonald 2001).
The Symbol Digit Modalities Test (SDMT)		SDMT is an easily administered brief cognitive performance tests. This test emphasizes working memory and speed processing.
Ratio treatment duration to disease duration		The ratio of duration of treatment (DT) to duration of disease (DD): DT/DD. Duration of treatment is the cumulative time of treatment with interferon-beta 1b. Duration of disease starts from the first presentation of MS symptoms

Trial Locations

Locations (1)

Cantonal Hospital of Saint Gallen; 🇨🇭 Saint Gallen, Switzerland